We also suggested that, by predicting glioma patients’ overall and/or progression-free survival in a univariate analysis, pro-angiogenic and/or pro-hypoxic miRNAs can be used as tools for monitoring patients, specifically with IDH-mutated low-grade tumors, since they are also measurable in plasma. This evidence concerns the gene IDH2 and central nervous system cancer.